SG11201804225PA - Inhibitors of influenza virus replication, application methods and uses thereof - Google Patents
Inhibitors of influenza virus replication, application methods and uses thereofInfo
- Publication number
- SG11201804225PA SG11201804225PA SG11201804225PA SG11201804225PA SG11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA SG 11201804225P A SG11201804225P A SG 11201804225PA
- Authority
- SG
- Singapore
- Prior art keywords
- guangdong
- international
- dongyangguang
- dongguan
- zhen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510908329 | 2015-12-09 | ||
PCT/CN2016/109079 WO2017097234A1 (en) | 2015-12-09 | 2016-12-08 | Inhibitors of influenza virus replication, application methods and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201804225PA true SG11201804225PA (en) | 2018-06-28 |
Family
ID=59012608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201804225PA SG11201804225PA (en) | 2015-12-09 | 2016-12-08 | Inhibitors of influenza virus replication, application methods and uses thereof |
Country Status (10)
Country | Link |
---|---|
US (2) | US10717732B2 (zh) |
EP (1) | EP3362451B1 (zh) |
JP (1) | JP6952695B2 (zh) |
CN (2) | CN109748915B (zh) |
AU (1) | AU2016368317B2 (zh) |
CA (1) | CA3005921A1 (zh) |
HK (1) | HK1254668A1 (zh) |
RU (1) | RU2737190C2 (zh) |
SG (1) | SG11201804225PA (zh) |
WO (1) | WO2017097234A1 (zh) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3005921A1 (en) * | 2015-12-09 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication |
CN109071567B (zh) * | 2016-05-19 | 2021-03-23 | 四川大学 | 抗流感小分子化合物及其制备方法和用途 |
CN107759571B (zh) | 2016-08-16 | 2021-03-02 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其使用方法和用途 |
WO2018041091A1 (en) | 2016-08-30 | 2018-03-08 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication, application methods and uses thereof |
CN109790159B (zh) | 2016-09-05 | 2020-01-14 | 广东众生睿创生物科技有限公司 | 抗流感病毒嘧啶衍生物 |
WO2018108125A1 (en) | 2016-12-15 | 2018-06-21 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
US11098042B2 (en) | 2017-01-05 | 2021-08-24 | Sunshine Lake Pharma Co., Ltd. | Inhibitors of influenza virus replication and uses thereof |
CN110446711B (zh) | 2017-03-02 | 2022-02-15 | 广东东阳光药业有限公司 | 流感病毒复制抑制剂及其用途 |
TWI778052B (zh) * | 2017-04-24 | 2022-09-21 | 美商共結晶製藥公司 | 流感病毒複製之抑制劑 |
CN109384783A (zh) * | 2017-08-09 | 2019-02-26 | 银杏树药业(苏州)有限公司 | 新型杂环化合物及其作为抗流感病毒抑制剂的医药用途 |
CN111971280A (zh) * | 2018-02-08 | 2020-11-20 | 耶路撒冷希伯来大学伊萨姆研究发展公司 | 杂芳基化合物、其药物组合物和其治疗用途 |
AU2019230497B2 (en) * | 2018-03-05 | 2021-08-05 | Guangdong Raynovent Biotech Co., Ltd. | Crystal form and salt form of pyridoimidazole compound and preparation method therefor |
CN110590768B (zh) * | 2018-06-13 | 2021-02-26 | 银杏树药业(苏州)有限公司 | 杂环化合物、其组合物及其作为抗流感病毒药物的应用 |
CN110967239B (zh) * | 2020-01-02 | 2022-05-10 | 国家地质实验测试中心 | 一种金属铬溶解氧化方法 |
CN117362318A (zh) * | 2020-07-10 | 2024-01-09 | 西藏海思科制药有限公司 | Pb2抑制剂及其制备方法和用途 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2403252C2 (ru) * | 2004-03-30 | 2010-11-10 | Вертекс Фармасьютикалз Инкорпорейтед | Азаиндолы, полезные в качестве ингибиторов jak и других протеинкиназ |
EP3141252B8 (en) * | 2009-06-17 | 2019-03-13 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
MX2013006846A (es) | 2010-12-16 | 2013-12-16 | Vertex Pharma | Inhibidores de la replicacion de los virus de la influenza. |
CN103492381A (zh) * | 2010-12-16 | 2014-01-01 | 沃泰克斯药物股份有限公司 | 流感病毒复制的抑制剂 |
AU2011343647A1 (en) | 2010-12-16 | 2013-05-02 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
EP2729465A2 (en) * | 2011-07-05 | 2014-05-14 | Vertex Pharmaceuticals Incorporated | Processes and intermediates for producing azaindoles |
UA118010C2 (uk) | 2011-08-01 | 2018-11-12 | Вертекс Фармасьютікалз Інкорпорейтед | Інгібітори реплікації вірусів грипу |
WO2013184985A1 (en) | 2012-06-08 | 2013-12-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
EP3851437A3 (en) | 2013-11-13 | 2021-11-03 | Vertex Pharmaceuticals Incorporated | Methods of preparing 1h-pyrrolo[2,3-b]pyridine derivates |
AU2014348840B2 (en) * | 2013-11-13 | 2019-06-06 | Vertex Pharmaceuticals Incorporated | Inhibitors of influenza viruses replication |
CN105848683A (zh) | 2013-11-13 | 2016-08-10 | 沃泰克斯药物股份有限公司 | 氮杂吲哚化合物的制剂 |
MX2017001752A (es) | 2014-08-08 | 2018-02-08 | Janssen Sciences Ireland Uc | Indoles para su uso en la infección por el virus de la gripe. |
EP3191489B1 (en) | 2014-09-08 | 2021-01-06 | Janssen Sciences Ireland Unlimited Company | Pyrrolopyrimidines for use in influenza virus infection |
CA3005921A1 (en) * | 2015-12-09 | 2017-06-15 | Sunshine Lake Pharma Co., Ltd. | Substituted-(pyrrolo[2,3-b]pyridin-3-yl)-pyrimidin derivatives and use thereof as inhibitors of influenza virus replication |
WO2017133664A1 (en) * | 2016-02-05 | 2017-08-10 | Savira Pharmaceuticals Gmbh | Bicyclic pyridine and pyrimidine derivatives and their use in the treatment, amelioration or prevention of influenza |
-
2016
- 2016-12-08 CA CA3005921A patent/CA3005921A1/en active Pending
- 2016-12-08 CN CN201910228694.7A patent/CN109748915B/zh active Active
- 2016-12-08 AU AU2016368317A patent/AU2016368317B2/en active Active
- 2016-12-08 CN CN201611123253.3A patent/CN106854205B/zh active Active
- 2016-12-08 US US15/780,231 patent/US10717732B2/en active Active
- 2016-12-08 JP JP2018529614A patent/JP6952695B2/ja active Active
- 2016-12-08 RU RU2018124993A patent/RU2737190C2/ru active
- 2016-12-08 WO PCT/CN2016/109079 patent/WO2017097234A1/en active Application Filing
- 2016-12-08 EP EP16872423.5A patent/EP3362451B1/en active Active
- 2016-12-08 SG SG11201804225PA patent/SG11201804225PA/en unknown
-
2018
- 2018-10-24 HK HK18113648.9A patent/HK1254668A1/zh unknown
-
2020
- 2020-06-09 US US16/897,256 patent/US11225477B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
KR20180088466A (ko) | 2018-08-03 |
US10717732B2 (en) | 2020-07-21 |
WO2017097234A1 (en) | 2017-06-15 |
RU2737190C2 (ru) | 2020-11-25 |
US20180346463A1 (en) | 2018-12-06 |
CA3005921A1 (en) | 2017-06-15 |
JP6952695B2 (ja) | 2021-10-20 |
RU2018124993A3 (zh) | 2020-02-05 |
EP3362451A1 (en) | 2018-08-22 |
CN109748915B (zh) | 2021-03-26 |
JP2018536681A (ja) | 2018-12-13 |
EP3362451B1 (en) | 2023-04-12 |
US11225477B2 (en) | 2022-01-18 |
AU2016368317B2 (en) | 2019-05-23 |
US20200299294A1 (en) | 2020-09-24 |
CN106854205A (zh) | 2017-06-16 |
CN106854205B (zh) | 2019-07-09 |
RU2018124993A (ru) | 2020-01-14 |
CN109748915A (zh) | 2019-05-14 |
AU2016368317A1 (en) | 2018-06-07 |
EP3362451A4 (en) | 2019-07-03 |
HK1254668A1 (zh) | 2019-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201804225PA (en) | Inhibitors of influenza virus replication, application methods and uses thereof | |
SG11201809874SA (en) | Systems and methods for locating a wireless device | |
SG11201808990QA (en) | Compositions for topical application of compounds | |
SG11201807252QA (en) | Anti-lag-3 antibodies | |
SG11201908604YA (en) | Fused imidazo-piperidine jak inhibitor compound | |
SG11201810171SA (en) | Kras g12c inhibitors | |
SG11201805645QA (en) | Lsd1 inhibitors | |
SG11201804312RA (en) | Microbubble-chemotherapeutic agent complex for sonodynamic therapy | |
SG11201804309PA (en) | Antibody molecules to april and uses thereof | |
SG11201907023UA (en) | Method of reducing neutropenia | |
SG11201909019SA (en) | Methods of treatment using a jak inhibitor compound | |
SG11201809024UA (en) | Cancer immunotherapy by immune activation or immune modulation via globo series antigens | |
SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
SG11201806284TA (en) | Low pressure separator having an internal divider and uses therefor | |
SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201805898RA (en) | Liquid composition comprising a multistage polymer, its method of preparation and its use | |
SG11201805001UA (en) | Method of treating influenza a | |
SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
SG11201901438VA (en) | Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate | |
SG11201805149XA (en) | Compositions comprising 15-hepe and methods of using the same | |
SG11201805204WA (en) | Nicotine particle capsule | |
SG11201900408RA (en) | Topical formulation for promoting wound healing | |
SG11201804440XA (en) | Chemical reprogramming of human glial cells into neurons with small molecule cocktail |